Cryosite (CTE.AX) Akcija Kursas
Cryosite Kursas
Per pastaruosius 19 metus Cryosite pajamos augo 6,9 % kasmet ir pasiekė 16,70 mln. AUD. Pelnas akcijai augo 4,1 % per metus per pastaruosius 19 metus. Cryosite grynoji marža 13,4 % yra išaugo palyginti su 11,6 % prieš kelerius metus. Esama kaina dividendo pajamingumas yra apie 1,64 %. Išmokų koeficientas yra apie 91 % pelno. Dividendas augo 5,5 % per metus per pastaruosius 13 metus.
Cryosite akcijos kaina
Gaukite šiuos duomenis per Eulerpool API
100 000 užklausų/mėn. nemokamai · be kortelės
Cryosite akcija ir akcijų analizė
Dažnai užduodami klausimai apie Cryosite akciją
The business model of Cryosite Ltd focuses on providing biobanking and cell therapy services. Cryosite specializes in the collection, storage, and distribution of human biological samples such as cord blood, tissue, and cells for medical and research purposes. The company allows individuals and families to preserve cord blood stem cells for potential future use in regenerative medicine. Cryosite also offers cell therapy manufacturing services to support personalized medicine and clinical trials. With its expertise and advanced technology, Cryosite aims to contribute to advancements in medical treatments and research, offering peace of mind to those seeking to preserve their biological materials.
Cryosite Ltd is primarily active in the biomedical and life sciences industries.
The main competitors of Cryosite Ltd in the market are companies like Stemlife, Singapore Cord Blood Bank, and CordLife Group Limited.
Cryosite Ltd, a reputable Australian company, has an intriguing history and background. Established in 2000, Cryosite has played a pivotal role in the field of biomedical services. The company specializes in secure storage and transportation of precious biological samples, supporting medical research, clinical trials, and stem cell transplant programs. With state-of-the-art facilities and stringent quality control measures, Cryosite has gained recognition as a trusted partner for numerous healthcare institutions and research organizations globally. Over the years, Cryosite Ltd has showcased its expertise in preserving and managing these life-changing resources, contributing significantly to advancements in healthcare and cutting-edge research.
Cryosite Ltd has achieved several significant milestones. Firstly, the company successfully established itself as a leading provider of comprehensive storage solutions for stem cells, reproductive tissues, and cord blood in Australia. Additionally, Cryosite Ltd expanded its services by offering advanced cryopreservation techniques, ensuring the long-term viability of stored materials. The company's commitment to quality led to accreditation by the Therapeutic Goods Administration (TGA) and attainment of ISO 9001 certification. Furthermore, Cryosite Ltd expanded its client base, attracting partnerships with major healthcare institutions and research organizations. These milestones demonstrate Cryosite Ltd's success in delivering trusted and state-of-the-art cryogenic storage services to its clients.
Cryosite Ltd primarily operates in Australia and New Zealand.
Cryosite Ltd is a leading company that values integrity, reliability, and innovation. With a strong corporate philosophy focused on providing premium services and solutions in the field of biobanking and reproductive services, Cryosite is committed to excellence. The company strives to ensure the utmost trust and transparency in all its operations, delivering high-quality cryopreservation services, cord blood banking, and stem cell research facilities. Cryosite Ltd continuously pushes boundaries through cutting-edge technology and strategic partnerships, aiming to meet the evolving needs of its customers and make a positive impact in the healthcare industry.
Pagal dabartinį kursą Cryosite akcija kainuoja 0,76 EUR (1,22 AUD).
Cryosite akcija (CTE.AX) kotiruojama 1 biržose, įskaitant: ASX (CTE.AX).
Cryosite Ltd is an Australian company that has been operating in the field of biological material storage for over 15 years. With a wide range of services and products, the company has established itself as a leading provider of cryo-storage solutions in Australia.
pelnas Cryosite yra 16,70 mln. AUD. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.
grynasis pelnas Cryosite yra 2,24 mln. AUD. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.
Kainų ir nuomos santykis (KGV) Cryosite šiuo metu yra 28,49. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti Cryosite akcijos vertę.
Kainų ir pardavimų santykis (KUV) Cryosite šiuo metu yra 3,81. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra Cryosite akcijos įvertinimo metrika.
Eulerpool kokybės balas Cryosite yra 7/10.
Cryosite ISIN yra AU000000CTE1. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.
Cryosite WKN yra 621943. WKN (Wertpapierkennnummer) yra šešiaženklė vokiška vertybinių popierių identifikacijos sistema.
Cryosite prekybos žymė yra CTE.AX. Ši biržos žymė naudojama Cryosite akcijoms prekiauti biržoje.
Cryosite akcija
Cryosite Pagrindiniai konkurentai
Cryosite Biržos simbolis
Cryosite FIGI
Visos Cryosite pagrindinės charakteristikos ir giluminė analizė
Mūsų akcijų analizė Cryosite akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai Cryosite. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes: